Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Free Report) VP Mary E. Godwin sold 35,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Nautilus Biotechnology Stock Up 2.7 %
Shares of NAUT opened at $3.08 on Friday. Nautilus Biotechnology, Inc. has a 52-week low of $2.19 and a 52-week high of $3.62. The firm has a market capitalization of $385.82 million, a PE ratio of -5.60 and a beta of 1.20. The firm has a 50-day moving average price of $2.59 and a 200 day moving average price of $2.59.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the business posted ($0.13) EPS. On average, equities analysts expect that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current year.
Institutional Investors Weigh In On Nautilus Biotechnology
Analyst Ratings Changes
Several research analysts have commented on NAUT shares. Guggenheim started coverage on shares of Nautilus Biotechnology in a research report on Thursday, June 27th. They issued a “buy” rating and a $6.00 target price for the company. Jefferies Financial Group started coverage on Nautilus Biotechnology in a research report on Monday, June 3rd. They issued a “hold” rating and a $3.00 target price on the stock.
Check Out Our Latest Report on Nautilus Biotechnology
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Recommended Stories
- Five stocks we like better than Nautilus Biotechnology
- What is Forex and How Does it Work?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Low P/E Ratio and What Does it Tell Investors?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- The 3 Best Retail Stocks to Shop for in August
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.